Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
Thursday, September 4, 2008 1 min read
Key Takeaway: Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
Full Press Release Details
Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent.